1. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6(5): 361–369.
2.
Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94(12): 4635–4644.
3.
Rolandsson O, Palmer JP. Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 2010; 53(7): 1250–1253.
4.
Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005; 48(11): 2195–2199.
5.
Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013; 36(4): 908–913.
6.
Buzzetti R, Tuomi T, Mauricio D, et al. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement from an International Expert Panel. Diabetes 2020; 69(10): 2037–2047.
7.
Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994; 11(3): 299–303.
8.
Fourlanos S, Perry C, Stein MS, et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006; 29(5): 970–975.
9.
Polish Diabetes Association. 2020 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology 2020; 9: 1–101.
10.
Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48(11): 2206–2212.
11.
Cernea S, Buzzetti R, Pozzilli P. Beta-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 2009; 32(Suppl. 2): S246–S252.
12.
Brophy S, Yderstraede K, Mauricio D, et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008; 31(3): 439–441.
13.
Chaillous L, Bouhanick B, Kerlan V, et al. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control. Diabetes Metab 2010; 36(1): 64–70.
14.
Thunander M, Thorgeirsson H, Törn C, et al. β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011; 164(2): 239–245.
15.
Schloot N, Eisenbarth GS. Isohormonal therapy of endocrine autoimmunity. Immunol Today 1995; 16(6): 289–294.
16.
Aaen K, Rygaard J, Josefsen K, et al. Dependence of antigen expression on functional state of beta-cells. Diabetes 1990; 39(6): 697–701.
17.
Zinman B, Kahn SE, Haffner SM, et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004; 53(12): 3193–3200.
18.
Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(4): 505–510.
19.
Yohena S, Penas-Steinhardt A, Muller C, et al. Immunological and clinical characteristics of latent autoimmune diabetes in the elderly. Diabetes Metab Res Rev 2019; 35(5): e3137.
20.
Lutgens MW, Meijer M, Peeters B, et al. Easily obtainable clinical features increase the diagnostic accuracy for latent autoimmune diabetes in adults: an evidence-based report. Prim Care Diabetes 2008; 2(4): 207–211.
21.
Appel SJ, Wadas TM, Rosenthal RS, et al. Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus. J Am Acad Nurse Pract 2009; 21(3): 156–159.
22.
Cousminer DL, Ahlqvist E, Mishra R, et al. First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. Diabetes Care 2018; 41(11): 2396–2403.
23.
Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43: S14–S31.
24.
World Health Organization [editorial]. Classification of diabetes mellitus. Geneva: WHO; 2019.
25.
Carlsson S. Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes. Front Physiol 2019; 10: 320.
26.
Rasouli B, Andersson T, Carlsson PO, et al. Smoking and the Risk of LADA: Results from a Swedish Population-Based Case-Control Study. Diabetes Care 2016; 39(5): 794–800.
27.
Palmer JP, Hampe CS, Chiu H, et al. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005; 54(Suppl. 2): S62–S67.
28.
Pozzilli P, Pieralice S. Latent Autoimmune Diabetes in Adults: Current Status and New Horizons. Endocrinol Metab (Seoul) 2018; 33(2): 147–159.
29.
Klingensmith GJ, Pyle L, Arslanian S, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33(9): 1970–1975.
30.
Szepietowska B, Wawrusiewicz-Kurylonek N, Krętowski A, et al. Endocrine autoimmunity in patients with Latent Autoimmune Diabetes in Adults (LADA) – association with HLA genotype. Endokrynol Pol 2016; 67(2): 197–201.
31.
Kawasaki E. Type 1 diabetes and autoimmunity. Clin Pediatr Endocrinol 2014; 23(4): 99–105.
